Full Text
Lifetime costs and life-years gained associated with apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Abstract

Authors

A.R. Harrington E.P. Armstrong P. Nolan D.C. Malone

Back to Volume 16, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×